BR112021024830A2 - Vesículas extracelulares microbianas processadas - Google Patents

Vesículas extracelulares microbianas processadas

Info

Publication number
BR112021024830A2
BR112021024830A2 BR112021024830A BR112021024830A BR112021024830A2 BR 112021024830 A2 BR112021024830 A2 BR 112021024830A2 BR 112021024830 A BR112021024830 A BR 112021024830A BR 112021024830 A BR112021024830 A BR 112021024830A BR 112021024830 A2 BR112021024830 A2 BR 112021024830A2
Authority
BR
Brazil
Prior art keywords
extracellular vesicles
processed microbial
microbial extracellular
processed
vesicles
Prior art date
Application number
BR112021024830A
Other languages
English (en)
Portuguese (pt)
Inventor
Alicia Ballok
Andrea Itano
Baundauna Bose
Brian Goodman
JH davitt Christopher
B Troy Erin
B Romano-Chernac Fabian
Holly Ponichtera
Loise Francisco-Anderson
Maria Sizova
Mark Bodmer
Nihal Okan
M R Carlton Sofia
A Cormack Taylor
Original Assignee
Evelo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evelo Biosciences Inc filed Critical Evelo Biosciences Inc
Publication of BR112021024830A2 publication Critical patent/BR112021024830A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112021024830A 2019-06-11 2020-06-11 Vesículas extracelulares microbianas processadas BR112021024830A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962860049P 2019-06-11 2019-06-11
US201962860029P 2019-06-11 2019-06-11
US202062979545P 2020-02-21 2020-02-21
US202062991767P 2020-03-19 2020-03-19
PCT/US2020/037210 WO2020252149A1 (en) 2019-06-11 2020-06-11 Processed microbial extracellular vesicles

Publications (1)

Publication Number Publication Date
BR112021024830A2 true BR112021024830A2 (pt) 2022-04-12

Family

ID=71950732

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112021024830A BR112021024830A2 (pt) 2019-06-11 2020-06-11 Vesículas extracelulares microbianas processadas
BR112021024754A BR112021024754A2 (pt) 2019-06-11 2020-06-11 Vesículas extracelulares microbianas secretadas

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112021024754A BR112021024754A2 (pt) 2019-06-11 2020-06-11 Vesículas extracelulares microbianas secretadas

Country Status (12)

Country Link
US (2) US20220249579A1 (https=)
EP (2) EP3982987A1 (https=)
JP (2) JP2022538765A (https=)
KR (2) KR20220020894A (https=)
CN (2) CN114650831A (https=)
AU (2) AU2020291434A1 (https=)
BR (2) BR112021024830A2 (https=)
CA (2) CA3143025A1 (https=)
CO (2) CO2022000041A2 (https=)
MX (2) MX2021015429A (https=)
TW (2) TW202128198A (https=)
WO (2) WO2020252144A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7402805B2 (ja) * 2018-02-06 2023-12-21 エヴェロ バイオサイエンシズ，インコーポレーテッド ベイロネラ（Ｖｅｉｌｌｏｎｅｌｌａ）の細菌を使用して癌及び免疫障害を処置するための組成物及び方法
KR102286042B1 (ko) * 2019-01-09 2021-08-03 주식회사 엠디헬스케어 데이노코커스 속 세균 유래 나노소포 및 이의 용도
JP7761556B2 (ja) * 2019-09-18 2025-10-28 リサーチ ディベロップメント ファウンデーション 代謝性疾患および障害を治療するための方法およびプロバイオティック組成物
TW202214276A (zh) * 2020-06-11 2022-04-16 美商艾弗洛生物科技股份有限公司 使用ｈａｒｒｙｆｌｉｎｔｉａ ａｃｅｔｉｓｐｏｒａ治療疾病和障礙之組成物及方法
WO2021252861A1 (en) * 2020-06-11 2021-12-16 Evelo Biosciences, Inc. Compositions and methods for treating diseases and disorders using megasphaera sp
AU2021296649A1 (en) * 2020-06-22 2023-02-09 Sl Bigen, Inc. Method and composition for enhancing cancer treatment efficacy of bacteria extracellular vesicles
EP4185307A1 (en) * 2020-07-21 2023-05-31 Evelo Biosciences, Inc. Veillonella parvula strain as an oral therapy for neuroinflammatory diseases
TW202227110A (zh) * 2020-09-21 2022-07-16 美商艾弗洛生物科技股份有限公司 用棲組織普雷沃菌調節免疫反應之組成物及方法
JP2024505207A (ja) * 2021-01-26 2024-02-05 エヴェロ バイオサイエンシズ，インコーポレーテッド プレボテラ（Ｐｒｅｖｏｔｅｌｌａ）細胞外小胞調製物
WO2022178209A1 (en) * 2021-02-19 2022-08-25 Evelo Biosciences, Inc. Compositions and methods for treating metabolic diseases and disorders using christensenellaceae bacteria
WO2022221183A1 (en) * 2021-04-12 2022-10-20 Evelo Biosciences, Inc. Fournierella extracellular vesicle preparations
WO2022251166A2 (en) * 2021-05-25 2022-12-01 Evelo Biosciences, Inc. Bacterial compositions comprising soy hemoglobin
CN117440819A (zh) * 2021-06-07 2024-01-23 Md保健株式会社 包含明串珠菌属细菌来源的囊泡的用于预防或治疗炎性疾病或癌症的组合物
WO2023114300A1 (en) * 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Fournierella massiliensis bacteria extracellular vesicle preparations
WO2023114293A1 (en) * 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Extracellular vesicle assays
WO2023146843A1 (en) * 2022-01-25 2023-08-03 Evelo Biosciences, Inc. Extracellular vesicle compositions and methods of use
WO2023239728A1 (en) * 2022-06-07 2023-12-14 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola extracellular vesicles
JP2024167772A (ja) * 2023-05-22 2024-12-04 マイクロアルジェコーポレーション株式会社 免疫賦活用組成物及び発現誘導用組成物
CN118006515B (zh) * 2024-04-08 2024-06-18 中国农业大学 一株乳酸乳球菌及其在制备治疗牛乳腺炎的药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102394638B1 (ko) * 2015-09-30 2022-05-09 (주)아모레퍼시픽 유산균 유래의 세포외 소낭을 포함하는 탈모 방지 또는 육모 촉진용 조성물
KR101858840B1 (ko) * 2016-01-15 2018-05-16 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
TW201906620A (zh) * 2017-07-05 2019-02-16 美商艾弗洛生物科技股份有限公司 使用動物雙岐桿菌乳亞種 (bifidobacterium animalis ssp. lactis) 治療癌症之組合物及方法
TW201920648A (zh) * 2017-08-29 2019-06-01 美商艾弗洛生物科技股份有限公司 使用布勞特氏(blautia)菌株治療癌症
EP3679057A1 (en) * 2017-09-08 2020-07-15 Evelo Biosciences, Inc. Extracellular vesicles from prevotella
EP3678693A1 (en) * 2017-09-08 2020-07-15 Evelo Biosciences, Inc. Bacterial extracellular vesicles
CN111601610A (zh) * 2017-11-14 2020-08-28 伊夫罗生物科学公司 使用布劳特氏菌属菌株治疗疾病的组合物和方法
BR112020009133A2 (pt) * 2017-11-15 2020-10-13 Evelo Biosciences, Inc. composições e métodos de tratamento de distúrbios imunológicos usando cepas de bactérias lactococcus imunomoduladoras
CN109580960A (zh) * 2019-01-14 2019-04-05 周明 细胞外囊泡的分离方法、以及检测细胞外囊泡表面标志物的方法和试剂盒

Also Published As

Publication number Publication date
CA3143025A1 (en) 2020-12-17
AU2020291434A1 (en) 2022-01-06
BR112021024754A2 (pt) 2022-04-19
CN114650831A (zh) 2022-06-21
KR20220020893A (ko) 2022-02-21
CA3143036A1 (en) 2020-12-17
TW202114718A (zh) 2021-04-16
EP3982987A1 (en) 2022-04-20
JP2022537684A (ja) 2022-08-29
JP2022538765A (ja) 2022-09-06
KR20220020894A (ko) 2022-02-21
CO2022000041A2 (es) 2022-01-17
US20220249579A1 (en) 2022-08-11
WO2020252149A1 (en) 2020-12-17
CN114096262A (zh) 2022-02-25
WO2020252144A1 (en) 2020-12-17
MX2021015427A (es) 2022-01-24
EP3982986A1 (en) 2022-04-20
CO2022000040A2 (es) 2022-01-17
US20220296654A1 (en) 2022-09-22
MX2021015429A (es) 2022-01-24
AU2020291003A1 (en) 2022-01-06
TW202128198A (zh) 2021-08-01

Similar Documents

Publication Publication Date Title
BR112021024830A2 (pt) Vesículas extracelulares microbianas processadas
CO2020004233A2 (es) Vesículas extracelulares bacterianas
BR112021016605A2 (pt) Preparações de membrana bacteriana
MX2020002660A (es) Vesiculas extracelulares de prevotella.
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
JOP20200011B1 (ar) مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp
CL2018003582A1 (es) Composiciones para modular la expresión de c9orf72 (divisional solicitud 201702567)
MX2017001279A (es) Usos y composiciones de la flagelina.
EP4620519A3 (en) Methods and compositions relating to chondrisomes from blood products
CY1119419T1 (el) C1-inh συνθεσεις για χρηση στην προληψη και αγωγη κληρονομικου αγγειοοιδηματος (ηαε)
MX375706B (es) Compuestos de inhibidor de autotaxina.
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
BR112019003577A2 (pt) métodos de tratamento da semente e produtos resultantes
EP4327808A3 (en) Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
MX2020009733A (es) Composiciones.
MX392199B (es) Composiciones farmaceuticas para terapia de combinacion
CO2019002889A2 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
UA120999C2 (uk) Естери оксаборолу та їх використання
MX2021006941A (es) Anelosomas para suministrar modalidades terapéuticas intracelulares.
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
MX392976B (es) Composiciones que comprenden cepas bacterianas.
MX385910B (es) Composiciones de fragancia que comprenden ciclohexanoato de etilo.
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]